AACR-NCI-EORTC--19th symposium. Molecular Targets and Cancer Therapeutics--Part 2.
Thomson Scientific, 77 Hatton Garden, London, EC1N 8JS, UK. benjamin.searle@thomson.com
Benjamin
B
Searle
Tracey
T
Collins
D000818:Animals; D000906:Antibodies / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D018841:HSP90 Heat-Shock Proteins / Q000037:antagonists & inhibitors; D056572:Histone Deacetylase Inhibitors; D006801:Humans; D024101:Mitochondrial Proteins / Q000037:antagonists & inhibitors; D009369:Neoplasms / Q000188:drug therapy*; D051496:Receptor, Fibroblast Growth Factor, Type 1 / Q000037:antagonists & inhibitors
D000906:Antibodies; D000970:Antineoplastic Agents; D018841:HSP90 Heat-Shock Proteins; D056572:Histone Deacetylase Inhibitors; D024101:Mitochondrial Proteins; C484385:SMCP protein, human; D051496:Receptor, Fibroblast Growth Factor, Type 1